Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Garland

Showing results (751-760 of 803) with videos related to

Pageof 81
Sort By:
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Journal of the National Cancer Institute|January 30, 2017
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized TrialsJoseph E Tota, Frank Struyf, Marko Merikukka, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
International Journal of Cancer|December 22, 2015
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE studyS Rachel Skinner, Cosette M Wheeler, Barbara Romanowski, et al.
The Lancet. Global Health|July 25, 2022
Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT)Andrew J B Vallely, Marion Saville, Steven G Badman, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
Science Immunology|May 5, 2023
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapyLihong Wang-Bishop, Blaise R Kimmel, Verra M Ngwa, et al.
Pageof 81

Showing results (751-760 of 803) with videos related to

Sort By:
Pageof 81
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Journal of the National Cancer Institute|January 30, 2017
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized TrialsJoseph E Tota, Frank Struyf, Marko Merikukka, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2014
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical diseaseElmar A Joura, Kevin A Ault, F Xavier Bosch, et al.
International Journal of Cancer|December 22, 2015
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE studyS Rachel Skinner, Cosette M Wheeler, Barbara Romanowski, et al.
The Lancet. Global Health|July 25, 2022
Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT)Andrew J B Vallely, Marion Saville, Steven G Badman, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Gynecologic Oncology|September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trialEdith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
The New England Journal of Medicine|February 19, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in womenElmar A Joura, Anna R Giuliano, Ole-Erik Iversen, et al.
Science Immunology|May 5, 2023
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapyLihong Wang-Bishop, Blaise R Kimmel, Verra M Ngwa, et al.
Pageof 81